EcoDrugPlus

Intermediate Conductance Calcium-Activated Potassium Channel Protein 4-Like

Ensembl ID : ENSCHAG00000000365
Gene Symbol: LOC105891927
2 Cross references
191 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSCHAG00000011802
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSCHAG00000001837
Gene Symbol: IDH2
3 Cross references
250 Possible Orthologues:

Kelch Like Ech Associated Protein 1

Ensembl ID : ENSCHAG00000025443
Gene Symbol: KEAP1
3 Cross references
189 Possible Orthologues:

Kinase Insert Domain Receptor (A Type Iii Receptor Tyrosine Kinase)

Ensembl ID : ENSCHAG00000010465
Gene Symbol: KDR
1 Cross references
198 Possible Orthologues:

Kinesin Family Member 11

Ensembl ID : ENSCHAG00000023033
Gene Symbol: KIF11
1 Cross references
199 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSCHAG00000006431
Gene Symbol: KIF5B
1 Cross references
274 Possible Orthologues:

Kinesin Family Member 5b

Ensembl ID : ENSCHAG00000014651
Gene Symbol: KIF5B
1 Cross references
274 Possible Orthologues:

Kinesin-Like Protein Kif11-A

Ensembl ID : ENSCHAG00000005141
Gene Symbol: LOC105906116
3 Cross references
200 Possible Orthologues:

Leukotriene A4 Hydrolase

Ensembl ID : ENSCHAG00000001018
Gene Symbol: LTA4H
3 Cross references
205 Possible Orthologues:

Leukotriene B4 Receptor

Ensembl ID : ENSCHAG00000007495
Gene Symbol: LTB4R
1 Cross references
142 Possible Orthologues:

Leukotriene B4 Receptor

Ensembl ID : ENSCHAG00000007770
Gene Symbol: LTB4R
1 Cross references
142 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).